Market Overview:
The global oncology generic injectable drugs market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, growing demand for affordable cancer treatments, and rising preference for generic drugs over branded drugs. Based on type, the global oncology generic injectable drugs market can be segmented into large molecule drugs and small molecule drugs. The large molecule drug segment is expected to account for a larger share of the market in 2018 owing to its high cost and longer duration of treatment as compared to small molecule drugs. However, the small molecule drug segment is projected to grow at a higher CAGR during the forecast period due its lower cost and shorter treatment duration as compared to large molecule Drugs. Based on application, the global oncology generic injectable Drugs market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Product Definition:
Oncology Generic Injectable Drugs are used to treat cancer. They are important because they can help save lives by attacking cancer cells.
Large Molecule Drugs:
Large molecule drugs are the ones that are composed of 10 or more atoms. These types of molecules have a greater therapeutic effect and they can penetrate more deeply into the cell. The most commonly used large molecule drug is Aspirin (ASA), which is an over-the-counter pain medication that reduces pain by blocking certain chemicals in the body that cause pain.
Small Molecule Drugs:
Small molecule drugs are the most commonly used injectable medicines. They are usually generic and have few if any brand names. Small molecules usually refer to any organic substance that has a molecular weight less than 1000 Da. Most small molecules are lipids or polymers. Some examples of small molecules include ethanol (alcohol), acetaminophen (Tylenol), digoxin, insulin, procainamide, phenobarbital sodium, and warfarin sodium.
Application Insights:
The hospital pharmacies segment held the largest share of 69.4% in 2017. This is attributed to the presence of a large patient base with cancer and increasing number of hospitals that offer oncology drugs as part of their regular medication. The online pharmacy segment is expected to witness lucrative growth during the forecast period owing to various benefits offered such as convenience, flexibility, and accessibility along with competitive pricing structure.
Generic injectable drugs are widely used for treatment purposes for various cancers such as lung, breast, colorectal, liver & biliary system among others due to their ability to stimulate cell growth or block tumor progression without causing any harmful effects on normal cells at therapeutic concentrations. These factors are anticipated to fuel market demand over the forecast period thus driving overall generic injectable drugs market growth during this period.
Regional Analysis:
North America dominated the global oncology generic injectable drugs market in 2017. The presence of key players, favorable reimbursement policies, and rising healthcare expenditure are some of the factors contributing to its growth. In addition, increasing awareness about COVID-19 therapies is expected to drive demand over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to factors such as growing population and prevalence of cancer coupled with improving healthcare infrastructure in emerging countries such as China and India are expected drive growth over next eight years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology generic injectable drugs market. According to World Health Organization (WHO), the number of new cases diagnosed with cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology generic injectable drugs in the coming years.
- Rising prevalence of chronic diseases: The rising prevalence of chronic diseases, such as diabetes and heart disease, is also fueling the demand for oncology generic injectable drugs market. According to Centers for Disease Control and Prevention (CDC), around half of American adults have one or more chronic health conditions, which are responsible for seven out ten deaths each year in U.S.. This growing trend will create a huge opportunity for players operating in this market over the forecast period.
- Technological advancements: The technological advancements are another key factor driving growth prospects for oncology generic injectable drugs market across globe .The advent of novel therapies and treatments has revolutionized management strategies employed against various types cancers resulting into increased uptake rates thereby propelling demand within this particular segment during forecast period .For instance , monoclonal antibodies therapy that harnesses immune system cells to fight tumors represent one such recent advance that is likely spur adoption rates over next few years .This aforementioned trend would be beneficial both patients as well as manufactures alike owing high margins associated with these products sales cycle .
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Generic Injectable Drugs Market Research Report
By Type
Large Molecule Drugs, Small Molecule Drugs
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Teva Pharmaceutical, Pfizer, AstraZeneca, Roche, Eli Lilly, GlaxoSmithKline, Novartis, Mylan, Natco Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Generic Injectable Drugs Market Report Segments:
The global Oncology Generic Injectable Drugs market is segmented on the basis of:
Types
Large Molecule Drugs, Small Molecule Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical
- Pfizer
- AstraZeneca
- Roche
- Eli Lilly
- GlaxoSmithKline
- Novartis
- Mylan
- Natco Pharma
Highlights of The Oncology Generic Injectable Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Large Molecule Drugs
- Small Molecule Drugs
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Generic Injectable Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology generic injectable drugs are medications used to treat cancer. They may be prescribed as part of a treatment plan for people with cancer, or they may be used to help prevent the development of cancer.
Some of the key players operating in the oncology generic injectable drugs market are Teva Pharmaceutical, Pfizer, AstraZeneca, Roche, Eli Lilly, GlaxoSmithKline, Novartis, Mylan, Natco Pharma.
The oncology generic injectable drugs market is expected to register a CAGR of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncology Generic Injectable Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncology Generic Injectable Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncology Generic Injectable Drugs Market - Supply Chain
4.5. Global Oncology Generic Injectable Drugs Market Forecast
4.5.1. Oncology Generic Injectable Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncology Generic Injectable Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oncology Generic Injectable Drugs Market Absolute $ Opportunity
5. Global Oncology Generic Injectable Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
5.3.1. Large Molecule Drugs
5.3.2. Small Molecule Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oncology Generic Injectable Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oncology Generic Injectable Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oncology Generic Injectable Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oncology Generic Injectable Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oncology Generic Injectable Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oncology Generic Injectable Drugs Demand Share Forecast, 2019-2026
9. North America Oncology Generic Injectable Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
9.7.1. Large Molecule Drugs
9.7.2. Small Molecule Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oncology Generic Injectable Drugs Demand Share Forecast, 2019-2026
10. Latin America Oncology Generic Injectable Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
10.7.1. Large Molecule Drugs
10.7.2. Small Molecule Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oncology Generic Injectable Drugs Demand Share Forecast, 2019-2026
11. Europe Oncology Generic Injectable Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oncology Generic Injectable Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
11.7.1. Large Molecule Drugs
11.7.2. Small Molecule Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oncology Generic Injectable Drugs Demand Share, 2019-2026
12. Asia Pacific Oncology Generic Injectable Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oncology Generic Injectable Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
12.7.1. Large Molecule Drugs
12.7.2. Small Molecule Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oncology Generic Injectable Drugs Demand Share, 2019-2026
13. Middle East & Africa Oncology Generic Injectable Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oncology Generic Injectable Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oncology Generic Injectable Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oncology Generic Injectable Drugs Market Size and Volume Forecast by Type
13.7.1. Large Molecule Drugs
13.7.2. Small Molecule Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oncology Generic Injectable Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oncology Generic Injectable Drugs Market: Market Share Analysis
14.2. Oncology Generic Injectable Drugs Distributors and Customers
14.3. Oncology Generic Injectable Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva Pharmaceutical
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Natco Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
